Pancreatic Cancer Research

ResearcherChiba UniversityActive in the last 2 years

Dai Mohri

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5021277077. Sources: OpenAlex.

Their work

Papers
18
Trials
0
Grants
0
Labs led
0
Collaborators
36
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: 6 papers · 2014: 2 papers · 2015: 3 papers · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 18

  1. Impact of Statin Use on Survival in Patients With Unresectable Pancreatic cancer Receiving Gemcitabine Plus Nab-Paclitaxel: A Multicenter Retrospective Study. Co-author DOI 10.1097/mpa.0000000000002411↗
  2. Soluble VCAM-1 promotes gemcitabine resistance via macrophage infiltration and predicts therapeutic response in pancreatic cancer. Co-author DOI 10.1038/s41598-020-78320-3↗
  3. Thromboembolisms in Advanced Pancreatic Cancer: A Retrospective Analysis of 475 Patients. Co-author DOI 10.1097/mpa.0000000000000889↗
  4. The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients. Co-author DOI 10.1007/s00432-014-1873-2↗
  5. Pancreatic cancer with malignant ascites: clinical features and outcomes. Co-author DOI 10.1097/mpa.0000000000000290↗
  6. [IPMN and pancreatic cyst as high risk of pancreatic cancer]. Co-author DOI 10.11405/nisshoshi.112.1474↗
  7. A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer. Co-author DOI 10.1007/s00280-014-2563-0↗
  8. Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. Co-author DOI 10.1007/s12029-014-9603-1↗
  9. Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monoth… Co-author DOI 10.1007/s00280-012-1981-0↗
  10. A retrospective analysis of early CA19‑9 change in salvage chemotherapy for refractory pancreatic cancer. Co-author DOI 10.1007/s00280-013-2313-8↗
  11. Risk factors and early signs of pancreatic cancer in diabetes: screening strategy based on diabetes onset age. Co-author DOI 10.1007/s00535-012-0622-z↗
  12. Diabetes is a useful diagnostic clue to improve the prognosis of pancreatic cancer. Co-author DOI 10.1016/j.pan.2013.03.013↗
  13. Risk for mortality from causes other than pancreatic cancer in patients with intraductal papillary mucinous neoplasm of the pancreas. Co-author DOI 10.1097/mpa.0b013e318270ea97↗
  14. Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals. Co-author DOI 10.1158/0008-5472.can-12-1453↗
  15. Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression. Co-author DOI 10.1007/s00535-011-0482-y↗
  16. A case of pancreatic cancer after heart transplantation. Co-author DOI 10.1536/ihj.53.205↗
  17. Duodenal invasion is a risk factor for the early dysfunction of biliary metal stents in unresectable pancreatic cancer. Co-author DOI 10.1016/j.gie.2011.04.046↗
  18. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci42754↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiroyuki Isayama · 17 shared papers, 2011–2025 · strength 0.77
  2. Yousuke Nakai · 15 shared papers, 2011–2025 · strength 0.72
  3. Kazuhiko Koike · 17 shared papers, 2011–2020 · strength 0.59
  4. Koji Miyabayashi · 14 shared papers, 2011–2020 · strength 0.48
  5. Hideaki Ijichi · 14 shared papers, 2011–2020 · strength 0.48
  6. Minoru Tada · 13 shared papers, 2011–2017 · strength 0.42
  7. Kei Saito · 6 shared papers, 2014–2025 · strength 0.41
  8. Suguru Mizuno · 12 shared papers, 2011–2017 · strength 0.40
  9. Naminatsu Takahara · 12 shared papers, 2011–2017 · strength 0.40
  10. Hirofumi Kogure · 12 shared papers, 2011–2017 · strength 0.40
  11. Saburo Matsubara · 5 shared papers, 2011–2025 · strength 0.35
  12. Keisuke Yamamoto · 9 shared papers, 2013–2020 · strength 0.34
  13. Takashi Sasaki · 10 shared papers, 2013–2015 · strength 0.32
  14. Tsuyoshi Hamada · 9 shared papers, 2011–2017 · strength 0.31
  15. Tsuyoshi Takeda · 2 shared papers, 2015–2025 · strength 0.23
  16. Takashi Sasaki · 2 shared papers, 2011–2025 · strength 0.22
  17. Ko Tomishima · 1 shared paper, 2025 · strength 0.20
  18. Hiroki Oyama · 1 shared paper, 2025 · strength 0.20
  19. Makoto Ueno · 1 shared paper, 2025 · strength 0.20
  20. Mitsuhiro Fujishiro · 1 shared paper, 2025 · strength 0.20
  21. Kazumichi Kawakubo · 7 shared papers, 2011–2015 · strength 0.19
  22. Naoki Sasahira · 7 shared papers, 2011–2015 · strength 0.19
  23. Harold L. Moses · 3 shared papers, 2011–2020 · strength 0.14
  24. Kazunaga Ishigaki · 3 shared papers, 2015–2017 · strength 0.13
  25. Masao Omata · 4 shared papers, 2011–2013 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.